GSK plc (GSK) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2022)
GSK's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
GSK Revenue Analysis (2014–2025)
As of March 1, 2026, GSK plc (GSK) generated trailing twelve-month (TTM) revenue of $31.95 billion, reflecting slight decline in growth of -2.6% year-over-year. The most recent quarter (Q4 2025) recorded $7.90 billion in revenue, down 7.5% sequentially.
Looking at the longer-term picture, GSK's 5-year compound annual growth rate (CAGR) stands at +5.6%, indicating steady revenue expansion. The company achieved its highest annual revenue of $33.75 billion in 2019.
Revenue diversification analysis shows GSK's business is primarily driven by Sub Total (100%). With over half of revenue concentrated in Sub Total, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MRK (+1.3% YoY), PFE (-1.6% YoY), and SNY (+8.9% YoY), GSK has underperformed the peer group in terms of revenue growth. Compare GSK vs MRK →
Peer Comparison
Compare GSK's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GSKCurrent | $32.0B | -2.6% | +5.6% | 21.9% | |
| MRK | $65.0B | +1.3% | +9.4% | 41.2% | |
| PFE | $62.6B | -1.6% | +8.5% | 24.7% | |
| SNY | $46.7B | +8.9% | +4.6% | 13.6% | |
| GRFS | $7.2B | +7.3% | +7.2% | 16.5% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $31.95B | +1.8% | $23.18B | 72.5% | $7.01B | 21.9% |
| 2024 | $31.38B | +3.5% | $22.33B | 71.2% | $4.02B | 12.8% |
| 2023 | $30.33B | +3.4% | $21.76B | 71.8% | $6.75B | 22.2% |
| 2022 | $29.32B | +18.7% | $19.77B | 67.4% | $6.43B | 21.9% |
| 2021 | $24.70B | +1.4% | $16.53B | 66.9% | $4.36B | 17.6% |
| 2020 | $24.35B | -27.8% | $16.43B | 67.4% | $5.98B | 24.6% |
| 2019 | $33.75B | +9.5% | $21.89B | 64.9% | $6.96B | 20.6% |
| 2018 | $30.82B | +2.1% | $20.58B | 66.8% | $5.48B | 17.8% |
| 2017 | $30.19B | +8.2% | $19.84B | 65.7% | $4.09B | 13.5% |
| 2016 | $27.89B | +16.6% | $18.60B | 66.7% | $2.60B | 9.3% |
See GSK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GSK Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GSK vs AGIO
See how GSK stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GSK's revenue growth accelerating or slowing?
GSK revenue growth slowed to -2.6%, below the 5-year CAGR of +5.6%. TTM revenue is $32.0B. The deceleration marks a shift from historical growth rates.
What is GSK's long-term revenue growth rate?
GSK plc's 5-year revenue CAGR of +5.6% reflects the variable expansion pattern. Current YoY growth of -2.6% is near this long-term average.
How is GSK's revenue distributed by segment?
GSK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.